ArticleJournal of translational medicine2025
Hypoxic migrasomes drive colorectal cancer liver metastasis by mediating CD5L
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- A hypoxia-responsive migrasome-related lncRNA signature predicts prognosis and suggests the MSC-AS1/ITGA5 axis as a potential therapeutic target in head and neck squamous cell carcinoma.Functional & integrative genomics · 2026Article
- CD147-positive migrasome macropinocytosis promotes HCC sorafenib resistance via inducing vasculogenic mimicry triggered by PI3K/AKT/TWIST1 signaling.Cell death & disease · 2026Article
- Migrasomes program tissue microenvironment: from physiology to oncology, future perspectives in clinical advances.Journal of the National Cancer Center · 2026Review
- Mitochondria transfer: intercellular communication and tumor microenvironment dynamics.Cell communication and signaling : CCS · 2026Review
- TMEM45 protein family - Ancient residents of the cell endomembrane.Frontiers in molecular biosciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveMigrasomes are a newly discovered class of extracellular vesicles, yet their roles in colorectal cancer (CRC) metastasis remain poorly understood. This study aimed to investigate the functional significance of CRC-derived migrasomes, particularly under hypoxic conditions, in promoting liver metastasis and modulating the tumor immune microenvironment.
methodsMigrasomes in CRC tissues and cells were characterized using transmission electron microscopy or immunofluorescence. A mouse liver metastasis model and single-cell RNA sequencing (scRNA-seq) were employed to explore functional outcomes and cellular interactions.
resultsMigrasome structures were observed in both primary CRC and metastatic liver tissues, and live-cell imaging revealed hypoxic CRC cells released increased numbers of migrasomes. In vivo imaging demonstrated hepatic accumulation of hypoxic migrasomes and enhanced liver metastasis in mice. ScRNA-seq of liver metastases revealed that hypoxic migrasomes reprogrammed the tumor microenvironment, notably expanding a Tmem45a⁺ fibroblast subset with myofibroblast features and promoting CD5L⁺ macrophage differentiation with elevated efferocytic capacity. Mechanistically, NRP2, enriched in migrasomes derived from hypoxic CRC cells, was transferred to macrophages, binding with PROX1 to drive CD5L expression and upregulate of efferocytosis receptors. NRP2 knockdown in CRC cells abrogated migrasome-induced CD5L⁺ macrophage polarization and impaired apoptotic tumor cell clearance.
conclusionThese findings demonstrate that hypoxic CRC-derived migrasomes facilitate liver metastasis by reprogramming stromal and immune compartments, particularly through NRP2/PROX1-mediated education of macrophages toward a pro-efferocytic CD5L⁺ phenotype. Our study reveals a previously unrecognized intercellular communication axis involving migrasomes in CRC progression and provides a potential therapeutic target for metastatic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.